Key result
Adherent use of ACEIs/ARBs in patients with end-stage renal disease on hemodialysis did not reduce all-cause mortality but was associated with increased risks of cardiovascular events compared to nonusers.
Why the study?
Do ACEIs or ARBs reduce mortality and cardiovascular events in patients with ESRD on hemodialysis?
Cohort (n=15,432)
Do ACEIs or ARBs reduce mortality and cardiovascular events in patients with ESRD on hemodialysis?
Answers are grounded in this paper and cite their sources.
In patients on hemodialysis, the use of ACEIs or ARBs does not appear to confer the expected cardiovascular and mortality benefits and may be associated with increased cardiovascular events.
Patients with end-stage renal disease (ESRD) who are on hemodialysis have high risk of vascular diseases. Our study sought to examine whether angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin type 1 receptor blockers (ARBs) could reduce the frequencies of cardiovascular and cerebrovascular events in patients receiving hemodialysis using the medication possession ratio (MPR) method of analysis.This retrospective cohort study identified cases of ESRD with dialysis from the National Health Insurance Research Database between 1999 and 2006, and used Cox-regression methods to evaluate risk of poor outcomes. Primary outcomes, including death from any cause, and secondary outcomes, including admission for stroke, myocardial infarction, and heart failure, were examined.Compared to the nonuser group, the adjusted HRs for mortality of the nonadherence group and the adherence group were 0.81 (95% CI: 0.76-0.86) and 0.98 (95% CI: 0.86-1.13), respectively. Cardiovascular events were more frequent in patients with ESRD receiving ACEIs /ARBs than in nonusers. Compared with nonusers, the hazard of secondary outcome significantly increased in the nonadherence group or adherence group in 10 years follow-up.Compared with patients with diabetes or chronic kidney disease, patients on hemodialysis may not experience the same cardiovascular and cerebrovascular benefits from ACEIs/ARBs use.
No takes yet. Share an insight, caveat, or question.
Liao et al. (2017) conducted a cohort in End-stage renal disease on hemodialysis (n=15,432). Angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin type 1 receptor blockers (ARBs) vs. Nonusers was evaluated on All-cause mortality (HR 0.98, 95% CI 0.86-1.13, p=0.801). Adherent use of ACEIs/ARBs in patients with end-stage renal disease on hemodialysis did not reduce all-cause mortality but was associated with increased risks of cardiovascular events compared to nonusers.
Synapse has enriched 10 related papers. Consider them for comparative context: